Talk:Vedolizumab

Cost

Vedolizumab (Entyvio) is one of those very expensive drugs that insurers often refuse to authorize. It was discussed in a story in ProPublica:

https://www.propublica.org/article/unitedhealth-healthcare-insurance-denial-ulcerative-colitis

UnitedHealthcare Tried to Deny Coverage to a Chronically Ill Patient. He Fought Back, Exposing the Insurer’s Inner Workings.

by David Armstrong, Patrick Rucker and Maya Miller

ProPublica

2 February 2023

It's hard to get a meaningful price for an expensive drug, but one reported figure in a WP:MEDRS was $406,629:

https://www.gastroenterologyandhepatology.net/archives/october-2016/the-cost-effectiveness-of-vedolizumab-for-inflammatory-bowel-disease-a-review-of-the-current-literature/

The Cost-Effectiveness of Vedolizumab for Inflammatory Bowel Disease: A Review of the Current Literature

Gastroenterology & Hepatology

October 2016 12(10):617-621

Yecheskel Schneider, Monica Saumoy, Shirley Cohen-Mekelburg, Adam F. Steinlauf, and Ellen J. Scherl

--Nbauman (talk) 14:13, 28 June 2023 (UTC)

@Nbauman - Your comment implies that the drug costs much more than it does. It is pricey, alright, but per the Gastroenterology and Hepatology article you reference, the cost of vedolizumab was $301,969/MH. "MH" is defined as "The goals of biologic therapy are mucosal healing (MH) and reversal of the natural history of progressive structural damage due to chronic inflammation." That could happen over months or years.

Thank you, Wordreader (talk) 06:02, 27 December 2023 (UTC)

Edit Request: Add Subcutaneous Route of Administration

Edit Request: Add Subcutaneous (SC) to Routes of Administration

• Entity/Article to update: Vedolizumab (Entyvio)
• Specific change requested: In the article's Chembox/Drugbox (the main information panel on the right), please update the routes_of_administration field to include "subcutaneous" (SC). Currently, it only lists "intravenous".
• Proposed replacement text for Route of Administration field: Intravenous (IV), subcutaneous (SC)
• Reason for change: The U.S. Food and Drug Administration (FDA) has approved subcutaneous administration of vedolizumab for maintenance therapy in adult patients with both moderately to severely active ulcerative colitis (approved September 2023) and Crohn's disease (approved April 2024). This route is now a standard, FDA-cleared method of delivery.

Supporting High-Quality Sources

Please use these independent, reliable medical sources to verify and cite the update:

1. FDA Approval for Ulcerative Colitis (Sept 2023) & Crohn's (April 2024):
   • Source: Gastroenterology & Endoscopy News (April 22, 2024). "FDA Grants New Indication for Subcutaneous Entyvio."
   • URL: https://www.gastroendonews.com/Inflammatory-Bowel-Disease/Article/04-24/entyvio-vedolizumab-subcutaneous-version-FDA-approved/73542
2. FDA Approval for Crohn's Disease Maintenance (April 2024):
   • Source: Pharmacy Times (April 19, 2024). "FDA Approves Vedolizumab for Maintenance Therapy to Treat Crohn Disease."
   • URL: https://www.pharmacytimes.com/view/fda-approves-vedolizumab-for-maintenance-therapy-to-treat-crohn-disease
3. Clinical Trial Basis (VISIBLE 2):
   • Trial Identifier: ClinicalTrials.gov NCT02611817 (VISIBLE 2 Study of Subcutaneous Vedolizumab in Crohn's Disease).

Thank you to the volunteer editors for reviewing and helping to keep this medical entry accurate and up-to-date! Lee.eversana (talk) 15:37, 27 May 2026 (UTC)

 Done Spencer^T•C 04:01, 29 May 2026 (UTC)